A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

NCT06737731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumors

Interventions

DRUG: SHR-1681

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.